Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Sucrose-formulated rFVIII: a safe and effective second-generation factor VIII developed by Bayer

Aug. 19, 1999

Novel platelet ADP inhibitors reported by Cor Therapeutics

Aug. 18, 1999

CPMP declines to recommend approval of saruplase marketing application

Aug. 18, 1999

Sanofi-Synthelabo, Akzo Nobel collaborate in the study of factor Xa inhibitors

Aug. 18, 1999

Clot buster eptifibatide now on the market in U.K.

Aug. 17, 1999

PolyMASC announces factor VIII research agreement with Bayer

Aug. 17, 1999

Factor Xa inhibitors from DuPont with potent antithrombotic activity in rabbits

Aug. 12, 1999

Preliminary results of SYMPHONY indicate that Xubix is effective in acute coronary syndromes

Aug. 9, 1999

Teijin prepares factor Xa inhibitor series

Aug. 6, 1999

Health Canada approves Integrilin for marketing

Aug. 6, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...